

# DTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO-Recommended NRTI Backbone

Michael Aboud,<sup>1</sup> Carlos Brites,<sup>2</sup> Hongzhou Lu,<sup>3</sup> Khuanchai Supparatpinyo,<sup>4</sup> Luis Hercilla,<sup>5</sup> Jörg Sievers,<sup>1</sup> Maria Claudia Nascimento,<sup>1</sup> Judy Hopking,<sup>6</sup> Mark Underwood,<sup>7</sup> Danae Brown,<sup>8</sup> Martin Gartland,<sup>7</sup> Kimberly Smith<sup>7</sup>

<sup>1</sup>ViiV Healthcare, Brentford, UK; <sup>2</sup>Federal University of Bahia, Salvador, Brazil; <sup>3</sup>Fudan University, Shanghai, China; <sup>4</sup>Chiang Mai University, Chiang Mai, Thailand; <sup>5</sup>Hospital Nacional Alberto Sabogal Sologuren, Callao, Peru; <sup>6</sup>GlaxoSmithKline, Uxbridge, UK; <sup>7</sup>ViiV Healthcare, Research Triangle Park, NC, USA; <sup>8</sup>ViiV Healthcare, Abbotsford, Australia


## Introduction

- There remains a need to optimize second-line antiretroviral therapy (ART) in resource-limited settings
- DAWNING is a noninferiority study comparing dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) with a current World Health Organization (WHO)-recommended regimen of lopinavir/ritonavir (LPV/r) + 2 NRTIs in HIV-1-infected adults failing first-line therapy (HIV-1 RNA  $\geq 400$  c/mL) with a non-nucleoside reverse transcriptase inhibitor (NNRTI) + 2 NRTIs (ClinicalTrials.gov identifier, NCT02227238)
- Week 24 secondary endpoint (% HIV-1 RNA  $< 50$  c/mL; snapshot) data were presented at the International AIDS Society Conference on HIV Science in 2017<sup>1</sup>
- Prior to a 24-week interim analysis, the study's Independent Data Monitoring Committee recommended discontinuation of the LPV/r arm due to superior efficacy of DTG + 2 NRTIs based on available data; the study protocol was amended to allow participants receiving ongoing LPV/r to switch to the DTG arm

## Methods

- Patients were randomized (1:1) to 52 weeks of open-label treatment with DTG or LPV/r combined with 2 investigator-selected NRTIs (Figure 1)
  - Key eligibility criteria: taking first-line 2 NRTIs + NNRTI regimen for  $\geq 6$  months; virologic failure (HIV-1 RNA  $\geq 400$  c/mL on 2 occasions); and no primary viral resistance to protease inhibitors or integrase strand transfer inhibitors (INSTIs)
  - Investigator-selected NRTIs included  $\geq 1$  fully active NRTI based on viral genotypic resistance testing at screening
  - Stratification: by HIV-1 RNA ( $\leq 100,000$  c/mL or  $> 100,000$  c/mL) and number of fully active NRTIs in the investigator-selected study background regimen (2 or  $< 2$ )

Figure 1. DAWNING Study Design



- Post-hoc efficacy analyses were performed based on whether WHO-recommended second-line NRTIs were chosen per participants' first-line NRTIs; 59 participants not taking WHO-recommended first-line NRTIs were excluded
  - WHO-recommended second-line NRTIs were defined as tenofovir disoproxil fumarate (TDF) + (emtricitabine [FTC] or lamivudine [3TC]) and zidovudine (AZT) + 3TC when (AZT or stavudine [d4T]) + 3TC and TDF + (FTC or 3TC), respectively, were used as first-line NRTIs<sup>2</sup>

## Results

- Of the 968 patients screened for the study, 627 (DTG group, n=312; LPV/r group, n=315) were randomly assigned to receive study medication, and 624 received  $\geq 1$  dose (DTG group, n=312; LPV/r group, n=312)
- 58 investigational centers in Argentina, Brazil, Chile, China, Colombia, Kenya, Mexico, Peru, Romania, the Russian Federation, South Africa, Thailand, and Ukraine randomized  $\geq 1$  study participant
- The most common reason for screening failure was not meeting inclusion criteria
  - Most common reason was HIV-1 RNA  $< 400$  c/mL in 134 patients (14%)
  - Only 78 (8%) were screen failures due to not having 1 fully active NRTI available
- Similar proportions of participants received either AZT + 3TC or TDF + (FTC or 3TC) as part of the second-line regimen within and across groups (Table)

Table. Prior ART and Background NRTIs Received at Day 1


	DTG (n=312)	LPV/r (n=312)
<b>First-line agent, n (%)</b>		
Efavirenz	242 (78)	242 (78)
TDF	181 (58)	186 (60)
AZT	89 (29)	89 (29)
<b>Second-line NRTI, n (%)</b>		
AZT + 3TC	131 (42)	121 (39)
TDF + (FTC or 3TC)	128 (41)	134 (43)
TDF + AZT	36 (12)	40 (13)
ABC + 3TC	7 (2)	7 (2)
Other <sup>a</sup>	10 (3)	10 (3)

ABC, abacavir. <sup>a</sup>Includes AZT + ABC, AZT + TDF + 3TC, and TDF + ABC.

- At Week 24, DTG + 2 NRTIs was superior to LPV/r + 2 NRTIs, with 82% (257/312) and 69% (215/312) of participants, respectively, achieving HIV-1 RNA  $< 50$  c/mL (adjusted difference, 13.8%; 95% confidence interval [CI], 7.3-20.3;  $P < 0.001$ ).<sup>1</sup> The difference was mainly driven by lower rates of snapshot virologic nonresponse in the DTG group

- Overall, 90% of participants in the DTG group and 84% in the LPV/r group achieved the secondary efficacy endpoint of plasma HIV-1 RNA  $< 400$  c/mL at Week 24
- 56% (347/624) of participants received second-line NRTIs in accordance with the WHO algorithm, and their snapshot response rates within each arm were higher than those for participants who did not. Regardless of WHO-recommended NRTI use, response rates were higher with DTG- versus LPV/r-based regimens (Figure 2)


Figure 2. Proportion of Participants With Plasma HIV-1 RNA  $< 50$  c/mL at Week 24 by Second-Line Background Regimen: Snapshot Analysis



<sup>a</sup>Proportion on DTG – proportion on LPV/r.  
<sup>b</sup>Proportion with WHO-recommended NRTIs – proportion without WHO-recommended NRTIs.

- Snapshot response rates were higher with DTG- versus LPV/r-based regimens regardless of the first-line to second-line NRTI change (Figure 3)

Figure 3. Proportion of Participants With Plasma HIV-1 RNA  $< 50$  c/mL at Week 24 by First- and Second-Line NRTI Choice: Snapshot Analysis



<sup>a</sup>Proportion on DTG – proportion on LPV/r (unadjusted).  
<sup>b</sup>Excludes participants who received d4T + 3TC in their first-line regimen (7 per treatment arm).

- The overall safety profile of DTG + 2 NRTIs was favorable compared with LPV/r + 2 NRTIs, with more drug-related adverse events reported in the LPV/r group<sup>1</sup>
- In this 24-week interim analysis, there were no treatment-emergent primary INSTI or NRTI resistance mutations in the DTG group through the randomization phase<sup>1</sup>

## Discussion

- 24-week interim data from the DAWNING study showed that DTG + 2 NRTIs is superior to LPV/r + 2 NRTIs in second-line therapy
- Subgroup analyses of virologic efficacy based on stratification of whether or not a WHO-recommended second-line NRTI background regimen was taken not only favor DTG versus LPV/r but also the regimen with WHO-recommended NRTIs within each treatment group
- One limitation of these analyses is that genotyping was used to select  $\geq 1$  fully active NRTI, and the resulting NRTI background regimen conforming to WHO guidance or not was incidental
- Outcomes from the SECOND-LINE and EARNEST studies suggest resistance testing may not be required in lieu of an appropriate algorithm for selection of second-line NRTIs<sup>3,4</sup>

## Conclusions

- In the DAWNING study, response rates were highest in participants receiving DTG + WHO-recommended second-line NRTIs
- Within each arm, study participants had higher response rates when receiving WHO-recommended versus other second-line NRTIs, reinforcing the WHO algorithm for NRTI selection in second-line treatment
- The DAWNING study provides important information to help guide second-line treatment decisions in resource-limited settings

**Acknowledgments:** This study was funded by ViiV Healthcare. We thank everyone who has contributed to the success of this study, including all study participants and their families; the DAWNING clinical investigators and their staff; and the ViiV Healthcare, GSK, and PAREXEL study team members. Editorial assistance and graphic design support for this poster were provided under the direction of the authors by MedThink SciCom and funded by ViiV Healthcare.

**References:** 1. Aboud M, Kaplan R, Lombaard J, et al. Superior efficacy of dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir/ritonavir (LPV/RTV) plus 2 NRTIs in second-line treatment: interim data from the DAWNING study. Abstract TUAB0105LB. Published at: 9th IAS Conference on HIV Science (IAS); July 23-26, 2017; Paris, France. 2. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. 2016. 3. SECOND-LINE Study Group. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. *Lancet*. 2013;381:2091-2099. 4. Paton NI, Kityo C, Thompson J, et al. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial. *Lancet HIV*. 2017;4:e341-e348.